Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers May 21, 2018
Pharmacy Choice - Pharmacy News - May 21, 2018

Pharmacy News

Today's Pharmaceutical and Pharmacy News
Daily News Topic:

FDA News
5/21/18 - AstraZeneca PLC Announces Lokelma approved in the US for the treatment of adults with hyperkalaemia
Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: "We are pleased by today's FDA approval of Lokelma as it enables us to help address a long-standing clinical need with a new medicine that offers rapid and sustained treatment for adults with hyperkalaemia. Steven Fishbane, MD, Profess
5/21/18 - AstraZeneca: FDA Approves Lokelma To Treat Adults With Hyperkalaemia
LONDON- British drug major AstraZeneca announced Monday that the US Food and Drug Administration or FDA has approved Lokelma, formerly ZS-9, for the treatment of adults with hyperkalaemia. The European Commission granted marketing authorisation for Lokelma in the European Union on March 22, 2018. Sean Bohen, Chief Medical Officer at AstraZeneca, sa
5/21/18 - Beta Bionics Receives IDE Approval from the FDA to Begin a Home-Use Clinical Trial Testing the New iLetâ?¢ Bionic Pancreas System
--Beta Bionics, Inc.â?? a medical technology company leveraging machine learning artificial intelligence to develop and commercialize the worldâ?? s first autonomous bionic pancreasâ?? today announced that it has received FDA approval to begin recruitment for home-use studies testing the insulin-only configuration of its iLet bionic pancreas system
5/21/18 - CERENOVUS Receives FDA Clearance For Next Generation Stent Retriever Device Used To Treat Ischemic Stroke
--CERENOVUS, part of the Johnson& Johnson Medical Devices Companies, announced today it has received 510 clearance from the U.S. Food and Drug Administration for EMBOTRAP II Revascularization Device, a next generation stent retriever used to capture and remove life-threatening blood clots from the brain following an ischemic stroke. In the ARISE II
5/21/18 - Dova Pharmaceuticals Announces U.S. FDA Approval of DOPTELET® (avatrombopag)
--Dova Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration has completed their Priority Review and approved DOPTELET ® for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure; this represents the first thrombopoietin receptor agonist approved in the United.
5/21/18 - Dova Receives FDA Nod For Bleeding Disorder Treatment; Rival Drug Awaits Clearance
The FDA announced its approval for Dova's New Drug Application for its lead product candidate Doptelet-- chemically avatrombopag-- indicated to treat thrombocytopenia in chronic liver disease patients who are scheduled to undergo a medical or dental procedure. The FDA said in the release that Doptelet is the first drug approved for the indication.

Chain Drug Review
Chain Drug Review Magazine Chain Drug Review, established in 1978 and published 21 times a year, is recognized as the premier news publication serving the entire chain drug store industry.
Featured Article from Chain Drug Review:
AWP suit settlement appealed
The National Association of Chain Drug Stores has appealed a U.S. District Court’s approval of settlements in the First DataBank Inc. and Medi-Span Inc. lawsuit. »read more

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement